EnteroMedics Inc. (ETRM) Issues Earnings Results
EnteroMedics Inc. (NASDAQ:ETRM) issued its earnings results on Tuesday. The medical device company reported ($0.91) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.00) by $0.09, Bloomberg Earnings reports. EnteroMedics had a negative net margin of 3,088.74% and a negative return on equity of 506.36%.
EnteroMedics (NASDAQ:ETRM) traded down 2.09% during mid-day trading on Tuesday, hitting $3.75. 286,598 shares of the stock traded hands. The stock has a 50 day moving average price of $4.70 and a 200 day moving average price of $5.56. The firm’s market cap is $25.90 million. EnteroMedics has a 12-month low of $1.75 and a 12-month high of $30.41.
A number of research analysts have issued reports on ETRM shares. Ladenburg Thalmann Financial Services started coverage on shares of EnteroMedics in a report on Wednesday, May 3rd. They issued a “buy” rating and a $11.00 target price for the company. Zacks Investment Research raised shares of EnteroMedics from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a report on Wednesday, July 12th.
EnteroMedics Company Profile
EnteroMedics Inc (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.